South African-American business tycoon Patrick Soon-Shiong has revealed that they are going to launch a SA Covid-19 and cancer vaccine initiative. Soon-0Shiong and President Cyril Ramaphosa informed the public about the ambitious plan during a virtual press briefing on Thursday.
Soon-Shiong is a billionaire, bioscientist and media guru, He is well known for inventing the drug Abraxane, known for its efficiency in treating lung, breast and pancreatic cancer. So the government asks him and believes that he will make a better vaccine which will be able to treat people, as it is we have COVID-19 vaccine in which people have already been taking.
The COVID-19 vaccine is one of the most fast invented vaccine because, it was created the same year when the outbreak was discovered. According to many it has saved their lives and now things have changed, because even those who contracted the virus thereafter did not die or suffer severely.
Content created and supplied by: Heist.money (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More